- Clinical Trials
- April 2025
- 60 Pages
Global
From €1323EUR$1,500USD£1,145GBP
- Report
- April 2025
- 200 Pages
Global
From €2196EUR$2,490USD£1,901GBP
- Report
- August 2025
- 189 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- August 2025
- 186 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- August 2025
- 189 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- August 2025
- 182 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- August 2025
- 194 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- August 2025
- 187 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- November 2024
- 150 Pages
Global
From €3395EUR$3,850USD£2,939GBP
€4277EUR$4,850USD£3,703GBP
- Report
- April 2025
- 250 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- April 2025
- 200 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- July 2025
- 175 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- April 2025
- 200 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- April 2025
- 200 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- March 2025
- 175 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- July 2025
Global
From €4321EUR$4,900USD£3,741GBP

Serotonin is a neurotransmitter found in the central nervous system (CNS) that plays a role in regulating mood, appetite, sleep, and other bodily functions. It is a key target for drugs used to treat depression, anxiety, and other mental health disorders. Serotonin-based drugs are typically selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). These drugs work by blocking the reuptake of serotonin, allowing it to remain active in the brain for longer periods of time.
The serotonin market is a subset of the larger CNS drug market, which is estimated to be worth billions of dollars. It is a highly competitive market, with many large pharmaceutical companies vying for market share. Companies in the serotonin market include Eli Lilly, Pfizer, GlaxoSmithKline, AstraZeneca, and Bristol-Myers Squibb. Show Less Read more